

Joohyuk Sohn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3498200/publications.pdf>

Version: 2024-02-01

141
papers

12,617
citations

81900

39
h-index

26613

107
g-index

143
all docs

143
docs citations

143
times ranked

10773
citing authors

#	ARTICLE	IF	CITATIONS
1	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012, 379, 633-640.	13.7	1,165
2	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
3	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2 ⁺ Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 2875-2884.	1.6	1,105
4	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	1.6	1,099
5	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	27.0	854
6	Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 307-316.	27.0	656
7	Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 904-915.	10.7	648
8	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1090-1100.	13.7	625
9	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor ⁺ Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy ⁺ MONARCH 2. <i>JAMA Oncology</i> , 2020, 6, 116.	7.1	572
10	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2 ⁺ , Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	1.6	478
11	Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). <i>Lab on A Chip</i> , 2011, 11, 1118.	6.0	389
12	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. <i>Annals of Oncology</i> , 2020, 31, 569-581.	1.2	253
13	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. <i>Annals of Oncology</i> , 2021, 32, 1571-1581.	1.2	225
14	Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. <i>Oncotarget</i> , 2016, 7, 24677-24687.	1.8	202
15	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. <i>International Journal of Cancer</i> , 2019, 145, 1179-1188.	5.1	199
16	Eliceprant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor ⁺ Positive, Human Epidermal Growth Factor Receptor 2 ⁺ Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	1.6	190
17	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 60-72.	10.7	161
18	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 1275-1289.	10.7	118

#	ARTICLE	IF	CITATIONS
19	Ad-mTERT ⁺ 19, a Conditional Replication-Competent Adenovirus Driven by the Human Telomerase Promoter, Selectively Replicates in and Elicits Cytopathic Effect in a Cancer Cell-Specific Manner. <i>Human Gene Therapy</i> , 2003, 14, 1415-1428.	2.7	111
20	Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. <i>Cancer</i> , 2014, 120, 642-651.	4.1	107
21	Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. <i>Biomaterials</i> , 2011, 32, 2314-2326.	11.4	104
22	Brain metastases from hepatocellular carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2009, 91, 307-313.	2.9	103
23	Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. <i>Gene Therapy</i> , 2006, 13, 1010-1020.	4.5	94
24	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. <i>Clinical Cancer Research</i> , 2022, 28, 851-859.	7.0	90
25	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1750-1759.	10.7	86
26	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	9.4	83
27	Risk of Lymphedema Following Contemporary Treatment for Breast Cancer. <i>Annals of Surgery</i> , 2021, 274, 170-178.	4.2	67
28	Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 215-221.	2.5	63
29	Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. <i>Oncology</i> , 2010, 79, 324-330.	1.9	62
30	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	7.1	62
31	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	2.4	62
32	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. <i>Journal of Clinical Oncology</i> , 2017, 35, 556-556.	1.6	60
33	Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients. <i>Cancer Research and Treatment</i> , 2018, 50, 801-812.	3.0	58
34	A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. <i>Annals of Oncology</i> , 2021, 32, 652-660.	1.2	56
35	Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. <i>Journal of Controlled Release</i> , 2007, 123, 164-171.	9.9	51
36	Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin. <i>Human Gene Therapy</i> , 2006, 17, 379-390.	2.7	49

#	ARTICLE	IF	CITATIONS
37	US Surveillance of Regional Lymph Node Recurrence after Breast Cancer Surgery. <i>Radiology</i> , 2009, 252, 673-681.	7.3	47
38	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 745-753.	2.5	46
39	Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. <i>Oncologist</i> , 2020, 25, e243-e251.	3.7	45
40	Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. <i>Cancer</i> , 2007, 109, 1829-1835.	4.1	40
41	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013, 21, 1751-1759.	2.2	38
42	Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.	7.0	35
43	Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). <i>Annals of Oncology</i> , 2013, 24, 1485-1490.	1.2	31
44	Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 679-686.	6.4	31
45	Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective. <i>Clinical Breast Cancer</i> , 2018, 18, e167-e178.	2.4	30
46	Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1123-1130.	2.5	29
47	A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1023-1023.	1.6	29
48	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 61-70.	7.0	27
49	Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. <i>International Journal of Clinical Oncology</i> , 2015, 20, 878-890.	2.2	26
50	Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1013-1013.	1.6	26
51	Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. <i>Cancer</i> , 2007, 109, 1845-1950.	4.1	25
52	A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. <i>Investigational New Drugs</i> , 2013, 31, 1300-1306.	2.6	23
53	Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram. <i>Neuro-Oncology</i> , 2012, 14, 1105-1113.	1.2	22
54	Role of Sonography in the Detection of Contralateral Metachronous Breast Cancer in an Asian Population. <i>American Journal of Roentgenology</i> , 2008, 190, 476-480.	2.2	21

#	ARTICLE	IF	CITATIONS
55	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 408-417.	7.0	21
56	Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2 ⁻) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. <i>Cancer Research</i> , 2021, 81, PD2-04-PD2-04.	0.9	20
57	Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results. <i>Annals of Surgical Treatment and Research</i> , 2017, 92, 331.	1.0	19
58	Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR. <i>Yonsei Medical Journal</i> , 2017, 58, 19.	2.2	19
59	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2 ⁻ advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA1008-LBA1008.	1.6	19
60	Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. <i>Journal of Breast Cancer</i> , 2016, 19, 76.	1.9	18
61	dI-VSVG-LacZ, a Vesicular Stomatitis Virus Glycoprotein Epitope-Incorporated Adenovirus, Exhibits Marked Enhancement in Gene Transduction Efficiency. <i>Human Gene Therapy</i> , 2003, 14, 1643-1652.	2.7	17
62	Prediction of short- and long-term survival for advanced cancer patients after ICU admission. <i>Supportive Care in Cancer</i> , 2015, 23, 1647-1655.	2.2	17
63	Chemotherapy-induced irreversible alopecia in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 527-533.	2.5	16
64	Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0149347.	2.5	16
65	Sonographic Surveillance for the Detection of Contralateral Metachronous Breast Cancer in an Asian Population. <i>American Journal of Roentgenology</i> , 2009, 192, 221-228.	2.2	15
66	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2 ⁻ advanced breast cancer: MONARCH 2 & 3 trials. <i>Cancer Science</i> , 2021, 112, 2381-2392.	3.9	15
67	Genomic Profiling of Premenopausal HR+ and HER2 ⁻ Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420.	3.0	15
68	Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. <i>PLoS ONE</i> , 2012, 7, e45127.	2.5	15
69	Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1087-1087.	1.6	15
70	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0152585.	2.5	14
71	Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. <i>International Journal of Cancer</i> . 2019, 145, 1669-1678.	5.1	14
72	A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10). <i>Tj ETQq0 0 0 rgB6 /Overlask 10 Tf 50</i>		

#	ARTICLE	IF	CITATIONS
73	CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator. <i>Oncotarget</i> , 2018, 9, 2622-2630.	1.8	13
74	Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. <i>Breast Care</i> , 2020, 15, 408-414.	1.4	13
75	Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 687-697.	2.5	13
76	Anaplastic Lymphoma Kinase Gene Copy Number Gain in Inflammatory Breast Cancer (IBC): Prevalence, Clinicopathologic Features and Prognostic Implication. <i>PLoS ONE</i> , 2015, 10, e0120320.	2.5	12
77	Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. <i>Cancer Research and Treatment</i> , 2020, 52, 907-916.	3.0	12
78	Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 309-313.	2.3	11
79	Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. <i>PLoS ONE</i> , 2017, 12, e0175048.	2.5	11
80	Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study. <i>Clinical Cancer Research</i> , 2019, 25, 2588-2600.	7.0	11
81	Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 689587.	2.8	11
82	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
83	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	6.4	9
84	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 399-412.	4.1	9
85	Multi-Disciplinary Treatment of a Rare Pelvic Cavity Ependymoma. <i>Yonsei Medical Journal</i> , 2007, 48, 719.	2.2	7
86	Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	7
87	Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. <i>Cancer Research and Treatment</i> , 2017, 49, 423-429.	3.0	7
88	Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3025-3025.	1.6	7
89	S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial. <i>BMC Cancer</i> , 2013, 13, 583.	2.6	6
90	Effect of primary tumor resection on overall survival in patients with stage IV breast cancer. <i>Breast Journal</i> , 2019, 25, 908-915.	1.0	6

#	ARTICLE	IF	CITATIONS
91	Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy. <i>Scientific Reports</i> , 2021, 11, 12105.	3.3	6
92	PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS587-TPS587.	1.6	6
93	Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigatorâ€™s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1100-1100.	1.6	6
94	Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. <i>Breast</i> , 2013, 22, 1205-1209.	2.2	5
95	Quality of life outcomes including neuropathyâ€ associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as firstâ€ line chemotherapy for HER2â€ negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq1 1 0.784314 5.0 BT / Over	2.2	5
96	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. <i>European Journal of Cancer</i> , 2021, 144, 341-350.	2.8	5
97	Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. <i>Cancer Research and Treatment</i> , 2021, 53, 1084-1095.	3.0	5
98	Final results of the randomized phase 2 <sc>LEO</sc> trial and bone protective effects of everolimus for premenopausal hormone receptorâ€ positive, <sc>HER2</sc>â€ negative metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	5.1	5
99	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539.	3.0	5
100	Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1017-1017.	1.6	5
101	Next generation sequencing and anti-cancer therapy. <i>Journal of the Korean Medical Association</i> , 2019, 62, 119.	0.3	4
102	Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 743-753.	2.5	4
103	acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physicianâ€™s choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS1100-TPS1100.	1.6	4
104	A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide. <i>Cancer Research and Treatment</i> , 2019, 51, 812-818.	3.0	4
105	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110619.	3.2	4
106	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptorâ€ positive (HR+), human epidermal growth factor receptor 2â€ negative (HER2â€) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1006-1006.	1.6	4
107	Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 255-262.	2.5	3
108	Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea. <i>Journal of Breast Cancer</i> , 2017, 20, 228.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). <i>Breast Cancer Research and Treatment</i> , 2019, 178, 367-377.	2.5	3
110	Genomic landscape of extraordinary responses in metastatic breast cancer. <i>Communications Biology</i> , 2021, 4, 449.	4.4	3
111	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3113-3113.	1.6	3
112	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2 ⁺ -Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5801-5809.	7.0	3
113	Safety of eribulin in Korean patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12031-e12031.	1.6	3
114	Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1072-1072.	1.6	3
115	Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1081-1081.	1.6	3
116	Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 107-116.	2.5	2
117	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021, 14, 1015-1025.	3.1	2
118	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1074-1074.	1.6	2
119	Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11579-e11579.	1.6	2
120	Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1108-TPS1108.	1.6	2
121	KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1118-TPS1118.	1.6	2
122	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. <i>Clinical Breast Cancer</i> , 2018, 18, e1165-e1172.	2.4	1
123	Expression of growth factor receptor family before and after targeted therapy in human epidermal growth factor receptor-2 positive breast cancer tissues. <i>Korean Journal of Clinical Oncology</i> , 2015, 11, 12-19.	0.1	1
124	338–Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study. , 2021, 9, A364-A364.		1
125	Molecular Characterization of BRCA1 c.5339T⟩C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 2405.	3.7	1
126	Copy number aberration burden on circulating tumor DNA predicts recurrence risk after neoadjuvant chemotherapy in patients with triple-negative breast cancer: Post-hoc analysis of phase III PEARLY trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 603-603.	1.6	1

#	ARTICLE	IF	CITATIONS
127	A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).. Journal of Clinical Oncology, 2022, 40, 1098-1098.	1.6	1
128	Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. Cancer Chemotherapy and Pharmacology, 2010, 66, 425-431.	2.3	0
129	The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. Cancer Nursing, 2018, 41, E49-E57.	1.5	0
130	On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study.. Journal of Clinical Oncology, 2021, 39, 1066-1066.	1.6	0
131	The long term outcome of clinical trial-based treatment comparing standard treatment for metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, 11106-11106.	1.6	0
132	Abstract P2-12-13: Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+ breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP). Cancer Research, 2022, 82, P2-12-13-P2-12-13.	0.9	0
133	Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG) Tj ETQq1 1 0.784314ogBT /Over	0.9	0
134	Abstract P1-17-09: Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor positive metastatic breast cancer. Cancer Research, 2022, 82, P1-17-09-P1-17-09.	0.9	0
135	Abstract P1-16-01: Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17). Cancer Research, 2022, 82, P1-16-01-P1-16-01.	0.9	0
136	Abstract P1-19-03: Phase II trial of durvalumab and tremelimumab in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean cancer study group trial (KCSG BR17-04). Cancer Research, 2022, 82, P1-19-03-P1-19-03.	0.9	0
137	Abstract PD6-07: Whole genome sequencing-based circulating tumor DNA profiling of metastatic breast cancer patients for molecular characterization and therapy response prediction. Cancer Research, 2022, 82, PD6-07-PD6-07.	0.9	0
138	Abstract P2-13-14: Pattern of recurrence after pathologic complete response after neoadjuvant chemotherapy in patients with early HER2-positive breast cancer: Real-world evidence. Cancer Research, 2022, 82, P2-13-14-P2-13-14.	0.9	0
139	Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09). Cancer Research and Treatment, 2022, , .	3.0	0
140	Impacts of subtypes on clinical feature and outcome of male breast cancer.. Journal of Clinical Oncology, 2022, 40, e12528-e12528.	1.6	0
141	Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTO trial.. Journal of Clinical Oncology, 2022, 40, 12084-12084.	1.6	0